NASDAQ$KALA
Kala Bio Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
KALA BIO reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
KALA BIO reported a net loss of $8.6 million for Q4 2023, compared to a net loss of $12.8 million for the same period in 2022. Research and development expenses increased to $4.7 million due to higher KPI-012 development costs. Cash and cash equivalents totaled $50.9 million as of December 31, 2023.
- Advanced Phase 2b CHASE trial of KPI-012 for PCED, targeting topline data by year-end 2024.
- Explored opportunities to expand KPI-012 into additional corneal indications.
- Cash resources as of December 31, 2023, along with proceeds from the March 2024 private placement, are expected to fund operations into 3Q 2025.
- Net loss for Q4 2023 was $8.6 million, an improvement compared to $12.8 million in Q4 2022.
Headline financials
Revenue & EPS history
Kala Bio · Revenue · Quarterly
$70K
Forward guidance
KALA BIO anticipates that its cash resources as of December 31, 2023, together with gross proceeds of $8.6 million received from its March 2024 private placement financing and anticipated funding under the CIRM award, will enable it to fund operations into the third quarter of 2025.
Tailwinds
- Advancing Phase 2b CHASE trial of KPI-012 for PCED.
- Targeting topline data from the CHASE trial by year-end 2024.
- Exploring opportunities to expand KPI-012 into additional corneal indications.
- Cash resources are expected to fund operations into 3Q 2025.
- KPI-012 may address a significant unmet need for PCED patients.
Headwinds
- Uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials.
- Uncertainties regarding availability and timing of data from clinical trials.
- KALA's ability to comply with the requirements under the CIRM award
- The sufficiency of cash resources and need for additional financing
- KALA’s ability to comply with the covenants under its loan agreement
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+1.5%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-4.7%
Avg return
30 days after
40%
14 / 35 earnings
Positive
+119.7%
Q4 2022
Best reaction
-18.3%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.6% | -17.4% | -17.7% | |
| Q3 2025 | -7.4% | -10.4% | -9.7% | |
| Q2 2025 | +2.0% | +9.9% | +103.2% | |
| Q1 2025 | -5.0% | +4.6% | +23.6% | |
| Q4 2024 | -1.5% | +1.5% | +0.0% | |
| Q3 2024 | -6.1% | -9.5% | -17.7% | |
| Q2 2024 | +3.2% | -1.7% | -1.7% | |
| Q1 2024 | -0.9% | -3.9% | -12.0% | |
| Q4 2023 | +0.3% | -2.4% | -21.0% | |
| Q3 2023 | -6.6% | -2.2% | +19.7% | |
| Q2 2023 | -6.5% | -8.4% | -7.9% | |
| Q1 2023 | -2.8% | +3.0% | -5.3% | |
| Q4 2022 | +119.7% | +114.5% | +48.0% | |
| Q3 2022 | +23.7% | +34.9% | -1.9% | |
| Q2 2022 | -3.4% | -4.6% | -1.7% | |
| Q1 2022 | +8.2% | -5.4% | -43.1% | |
| Q4 2021 | -16.6% | -25.1% | -61.9% | |
| Q3 2021 | +4.3% | -7.7% | -30.4% | |
| Q2 2021 | -6.3% | -4.8% | -2.7% | |
| Q1 2021 | -18.3% | -18.4% | -9.0% | |
| Q4 2020 | -17.0% | -17.6% | -21.4% | |
| Q3 2020 | -1.8% | +0.6% | +2.5% | |
| Q2 2020 | -2.7% | -2.5% | -13.2% | |
| Q1 2020 | -2.8% | +2.8% | +17.0% | |
| Q4 2019 | +3.5% | +1.6% | +1.3% | |
| Q3 2019 | +7.0% | -4.4% | +4.2% | |
| Q2 2019 | +1.2% | -0.6% | -20.6% | |
| Q1 2019 | -8.6% | -17.2% | -24.2% | |
| Q4 2018 | +1.0% | +6.6% | -1.6% | |
| Q3 2018 | -5.4% | -13.8% | -25.9% | |
| Q2 2018 | +1.6% | -3.9% | -8.5% | |
| Q1 2018 | +2.0% | +3.7% | -16.0% | |
| Q4 2017 | -7.1% | -7.4% | -7.4% | |
| Q3 2017 | -3.6% | +2.6% | +1.7% | |
| Q2 2017 | +5.4% | +6.2% | -3.7% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro